Release Date: June 5, 2020
Expiration Date: May 29, 2023
This activity offers CE credit for:
- Physicians (CME)
- Optometrists (COPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.
Jacque Duncan, MD
University of California, San Francisco
San Francisco, CA
Statement of Need
With more than 30 clinical trials currently underway for the treatment of inherited retinal diseases, clinicians need to understand the actions they can take to better manage their IRD patients and get them on the path to clinical trials as well as future therapies.
At the end of this CE activity, participants should be able to:
- Summarize inherited retinal diseases (IRDs) and their impact on patients
- Identify the benefits of IRD genetic testing, genetic counseling, and patient registries
- Review current clinical trials for emerging IRD therapies
Ophthalmologists and optometrists
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC and Foundation Fighting Blindness. CME Outfitters, LLC is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE Credit (Optometrists)
This activity, COPE Activity Number 119586, is accredited by COPE for continuing education for optometrists.
CME Outfitters will submit attendance to COPE within 30 days of completion.
It is the policy of CME Outfitters, LLC to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Duncan reports she received grants from Foundation Fighting Blindness; National Eye Institute; and the Larry L. Hillblom Foundation, Inc. She received research support from Acucela Inc.; Allergan; Biogen/Nightstarx. She served as a consultant for 4D Molecular Therapeutics (Data safety monitoring board member); AGTC; ProQR Therapeutics; and Spark Therapeutics, Inc. and has done consulting and or served on the advisory board for Biogen/NIghtstarx; Editas Medicine; Gyroscope Therapeutics; Horama; SparingVision; and Vedere.
Ben Shaberman (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclosure to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).